Unity Biotechnology, Inc.(UBX)
$0.20—Stale · unknown old
Unity Biotechnology, Inc.(UBX)
NASDAQ • Last print unknown ago
$0.20—Stale · unknown old
Buy10 analysts
Target $2.50+1149.4%
Key Metrics
TTMMarket Cap$3.44M
Revenue TTM$1.33M
Rev Growth YoY-30.2%
Price / Sales2.6x
Fwd P/E FY29E1.5x
Net Income TTM-$27.50M
Free Cash Flow-$22.04M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-149.0%
Return on Assets-69.0%
Debt / Equity (MRQ)3.62
Current Ratio (MRQ)2.62
EPS TTM$-1.54
PRICE
Prev Close
0.10
Open
0.20
Day Range—
52W Range0.10 – 3.10
0.10
3.10
3% of range
50-Day MA
0.14(+38.7%)
200-Day MA
0.09(+119.8%)
VOLUME & SIZE
Avg Volume
761.6K
FUNDAMENTALS
P/E (TTM)
-0.1x
Not profitable
EPS (TTM)
—
Div Yield (TTM)
No dividend
Beta
1.85
High vol
TECHNICAL
RSI (14)
81
Overbought
Upcoming Events
DEx-Dividend
In 90 days
Nov 27
PDividend Pay
In 90 days
Nov 27
UBX News
About
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Anirvan Ghosh
Website
Alexander Hieu NguyenChief Legal Officer & Head of Operations
Nathaniel E. DavidCo-Founder & Independent Director
Federico GrossiChief Medical Officer
Przemyslaw SapiehaChief Scientist
Alicia TozierChief Strategy Officer
Lynne Marie SullivanChief Financial Officer & Head of Corporate Development
Anirvan GhoshChief Executive Officer & Director
Jan van DeursenFounder